These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 3969066)

  • 1. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists.
    Kalani MY; Vaidehi N; Hall SE; Trabanino RJ; Freddolino PL; Kalani MA; Floriano WB; Kam VW; Goddard WA
    Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3815-20. PubMed ID: 14999101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors.
    Lee DYW; Liu J; Zhang S; Huang P; Liu-Chen LY
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1437-1440. PubMed ID: 28214075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?
    Colom M; Vidal B; Zimmer L
    Front Mol Neurosci; 2019; 12():255. PubMed ID: 31680859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.
    Shalgunov V; van Waarde A; Booij J; Michel MC; Dierckx RAJO; Elsinga PH
    Med Res Rev; 2019 May; 39(3):1014-1052. PubMed ID: 30450619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.
    Meade JA; Free RB; Miller NR; Chun LS; Doyle TB; Moritz AE; Conroy JL; Watts VJ; Sibley DR
    Psychopharmacology (Berl); 2015 Mar; 232(5):917-30. PubMed ID: 25231919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of 5-hydroxytryptamine-induced hyperpolarization of the rat superior cervical ganglion.
    Ireland SJ; Jordan CC
    Br J Pharmacol; 1987 Oct; 92(2):417-27. PubMed ID: 3676602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D1 receptors labelled with [3H]SCH23390 in rabbit cerebral cortex and neostriatum. Equilibrium binding, kinetics and selectivity.
    Reader TA; Grondin L; Montreuil B; Dewar KM
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Dec; 340(6):617-25. PubMed ID: 2575710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
    Braun A; Mouradian MM; Mohr E; Fabbrini G; Chase TN
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):631-5. PubMed ID: 2567345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solubilization and reconstitution of dopamine D1 receptor from bovine striatal membranes: effects of agonist and antagonist pretreatment.
    Srivastava LK; Ross GM; Bajwa SB; Mishra RK
    Neurochem Res; 1990 Jun; 15(6):647-57. PubMed ID: 1977093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
    Creese I; Sibley DR; Leff SE
    Fed Proc; 1984 Oct; 43(13):2779-84. PubMed ID: 6383871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive method for the quantitative determination of dopamine receptor subtypes.
    McGonigle P; Huff RM; Molinoff PB
    Ann N Y Acad Sci; 1984; 430():77-90. PubMed ID: 6331265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
    Leff SE; Hamblin MW; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):171-83. PubMed ID: 3969066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes.
    Hamblin MW; Leff SE; Creese I
    Biochem Pharmacol; 1984 Mar; 33(6):877-87. PubMed ID: 6712712
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.